0000939767false00009397672023-05-312023-05-31

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(a)On May 31, 2023, Exelixis, Inc. (Exelixis) held its 2023 Annual Meeting of Stockholders (the Annual Meeting) at its offices located at 1851 Harbor Bay Parkway, Alameda, CA 94502.

(b)The results of the matters submitted to a stockholder vote at the Annual Meeting were as follows:

1.Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2024, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal:

As previously disclosed on May 7, 2023, Dr. Lance Willsey resigned from the Company’s Board of Directors (Board) and did not stand for re-election. Accordingly, the foregoing voting results do not include votes cast for Dr. Willsey.

2.Ratification of Ernst & Young LLP as Exelixis’ independent registered public accounting firm: Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending December 29, 2023.

3.Approval, on an advisory basis, of the compensation of Exelixis’ named executive officers, as disclosed in the proxy statement (Say-on-Pay): Exelixis stockholders approved the Say-on-Pay proposal.

4.Approval, on an advisory basis, of the preferred frequency of shareholder advisory votes on the compensation of Exelixis’ named executive officers (Say-on-Pay Frequency): Exelixis stockholders approved the option of “1 Year” on the Say-on-Pay Frequency proposal.

(c)In accordance with the Board of Directors’ recommendation as set forth in Exelixis’ proxy statement for the Annual Meeting and consistent with the stated preference of Exelixis’ stockholders as reflected above, Exelixis determined that future stockholder advisory votes on executive compensation will be conducted on an annual basis, until the next stockholder advisory vote on this matter is held.

(d)No other matters were submitted for stockholder action.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.